Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs

Renal Failure

Volumn 32, Issue 2, 2010, Pages 192-197

  Robles, N R ^a   Romero, B ^b   De Vinuesa, E Garcia ^b   Snchez Casado, E ^b   Cubero, J J ^b  

^a Catedra de Riesgo Cardiovascular   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Hypertension; Lercanidipine; Proteinuria

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LERCANIDIPINE; TORASEMIDE; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; EPIGASTRIC PAIN; ERECTILE DYSFUNCTION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY FAILURE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77749279771     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903541135     Document Type: Article

References (44)

1. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and endstage renal disease in men. N Engl J Med. 1996;334:13-18.
2. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL. Blood pressure and renal function: Therapeutic implications. J Hypertens. 1996;14: 1259-1263.
3. Mandhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet. 1995; 345:749-751.
4. Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, Pennert K, Wedel H, Wikstrand J, Berglund G. Predictors of cardiovascular morbidity in treated hypertension: Results from the Primary Preventive Trial in Göteborg, Sweden. J Hypertens. 1985;3:167-176.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
6. Robles NR. Calcium antagonists and renal failure pro-gresión. Ren Fail. 2008;30:247-255.
7. Barrios V, Navarro A, Esteras A, Luque M, Romero J, Tamargo J, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Pressure. 2002;11:95-100.
8. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, on behalf of the COHORT Study Group. Toler-ability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15:932-940.
9. Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension. 2000;35: 775-779.
10. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, et al. Effect of lercanidipine compared with rami-pril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL Study (diabete, iperten-sione, albuminuria, lercanidipina). Diab Nutr Metab. 2004; 17:259-266.
11. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39 (Suppl. 1):S1-S246.
12. The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
13. Parving HH. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephr-opathy. J Hypertens. 1990;8:S187-S191.
14. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King A, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria and the progression of renal disease: The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762.
15. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood pressure lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963-1974.
16. Reams GP, Bauer JH. Acute and chronic effects of calcium antagonists on the essential hypertensive kidney. In Epstein M, Loutzenhiser R (eds.). Calcium antagonists and the kidney. Philadelphia: Hanley & Belfus; 1990:247-256.
17. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int. 1993;44:545-550.
18. Ichikawa I. Will angiotensin II receptor antagonists be reno-protective in humans? Kidney Int. 1996;50:684-692.
19. Lewis E, Huncksicker LG, Clarke WR, Berl T, Pons MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
20. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al., for the REIN 2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomized controlled trial. Lancet. 2005;365:939-946.
21. National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med. 1996;156: 1938-1947.
22. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different anti-hypertensive drugs in human diabetic nephr-opathy: An updated meta-analysis. Nephrol Dial Transplant. 1995;10 (Suppl. 9):39-45.
23. Palmer BF. Management of hypertension in patients with chronic kidney disease and diabetes. Am J Med. 2008;121: S16-S22.
24. Carmines PK, Navar LG. Disparate effects of Ca channel blockers on afferent and efferent arteriolar responses to ANG II. Am J Physiol. 1989;256:F1015-F1020.
25. Loutzenhiser R, Epstein M. Renal hemodynamic effects of calcium antagonists. In Epstein M, Loutzenhiser R (eds.). Calcium antagonists and the kidney. Philadelphia: Hanley & Belfus; 1990:33-74.
26. Fleming JT, Parekh N, Steinhausen M. Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol. 1987;253:F1157-F1163.
27. Dworkin LD. Effects of calcium channel blockers on glom-erular injury on experimental glomerular injury. J Am Soc Nephrol. 1990;1:S21-S27.
28. Kanno Y, Suzuki H, Okada H, Saruta T. Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet. J Cardiovasc Pharmacol. 1994;23:480-484.
29. Nagahama T, Hayashi K, Fujiwara K, Ozawa Y, Saruta T. Characterization of the renal action of pranidipine in the rat. Arzneimittel-Forsch. 2000;50:248-253.
30. Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension. 1991; 17:288-295.
31. Bidani AK, Schwartz MM, Lewis EJ. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol. 1987;252:F1003-F1010.
32. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical determinant of subsequent hypertension and glomerular injury. J Am Soc Nephrol. 1994;4:2023-2031.
33. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockers on pressures transmission and glomerular injury in rat remnant kidneys. J Clin Invest. 1995; 96:793-800.
34. Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999;55:1849-1860.
35. Bellinghieri G, Mazzaglia G, Savica V, Santoro D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: A multicenter randomized controlled trial. Ren Fail. 2003;25:681-689.
36. Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microal-buminuria: The AMANDHA study. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1347-1355.
37. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005;61:483-490.
38. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, et al. Effect of lercanidipine compared with rami-pril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diab Nutr Metab. 2004;17:259-266.
39. Robles NR, Ocon J, Gomez Campderá F, Manjon M, Pastor L, Herrera J, et al. Lercanidipine in chronic renal failure patients: The ZAFRA Study. Ren Fail. 2005;27:73-80.
40. Ishitmitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, et al. Efonidipine Reduces Proteinuria and Plasma Aldosterone in Patients with Chronic Glomerulonephritis. Hypertens Res 2007; 30: 621-626.
41. Düssing R. Angiotensin II-receptor blocker dosages: How high should we go? Int J Clin Pract. 2006;60:179-183.
42. Morisco C, Trimarco B. Efficacy and tolerability of lercanid-ipine in comparison to and in combination with atenolol in patients with mild to moderate essential hypertension in a double blind controlled study. J Cardiovasc Pharmacol. 1997;29 (Suppl. 2):S54-S58.
43. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolera-bility of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin. Exp. Res. 2000;12:375-379.
44. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonists (either nifedipine or amlodipine) versus high-dose calcium antagonists monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182-1187.